Lund University is celebrating 350 years.


Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

C(2)-ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 adipocytes.

  • Jie Mei
  • Lena Stenson
  • Tova Landström
  • Cecilia Holm
  • David Brindley
  • Vincent Manganiello
  • Eva Degerman
Publishing year: 2002
Language: English
Pages: 631-637
Publication/Series: Diabetes
Volume: 51
Issue: 3
Document type: Journal article
Publisher: American Diabetes Association

Abstract english

Cyclic nucleotide phosphodiesterase (PDE) 3B plays an important role in the antilipolytic action of insulin and, thereby, the release of fatty acids from adipocytes. Increased concentrations of circulating fatty acids as a result of elevated or unrestrained lipolysis cause insulin resistance. The lipolytic action of tumor necrosis factor (TNF)-alpha is thought to be one of the mechanisms by which TNF-alpha induces insulin resistance. Ceramide is the suggested second messenger of TNF-alpha action, and in this study, we used 3T3-L1 adipocytes to investigate the effects of C(2)-ceramide (a short-chain ceramide analog) on the expression and regulation of PDE3B and lipolysis. Incubation of adipocytes with 100 micromol/l C(2)-ceramide (N-acetyl-sphingosine) resulted in a time-dependent decrease of PDE3B activity, accompanied by decreased PDE3B protein expression. C(2)-ceramide, in a time- and dose-dependent manner, stimulated lipolysis, an effect that was blocked by H-89, an inhibitor of protein kinase A. These ceramide effects were prevented by 20 micromol/l troglitazone, an antidiabetic drug. In addition to downregulation of PDE3B, the antilipolytic action of insulin was decreased by ceramide treatment. These results, together with data from other studies on PDE3B and lipolysis in diabetic humans and animals, suggest a novel pathway by which ceramide induces insulin resistance. Furthermore, PDE3B is demonstrated to be a target for troglitazone action in adipocytes.


  • Endocrinology and Diabetes
  • Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors
  • Drug Interactions
  • Enzyme Inhibitors/pharmacology
  • Insulin/*pharmacology
  • Insulin Resistance
  • Isoquinolines/pharmacology
  • Tumor Necrosis Factor/pharmacology
  • Transcription Factors/genetics
  • Thiazoles/pharmacology
  • Non-U.S. Gov't
  • Support
  • Sphingosine/*analogs & derivatives/*pharmacology
  • Cytoplasmic and Nuclear/genetics
  • Receptors
  • Lipolysis/*drug effects
  • Mice
  • Chromans/pharmacology
  • Western
  • Blotting
  • Animal
  • 3'
  • 5'-Cyclic-Nucleotide Phosphodiesterase/analysis/*metabolism
  • 3T3 Cells
  • Adipocytes/*metabolism


  • Appetite Regulation
  • Insulin Signal Transduction
  • Molecular Endocrinology
  • ISSN: 1939-327X
Eva Degerman
E-mail: eva [dot] degerman [at] med [dot] lu [dot] se


Insulin Signal Transduction

+46 46 222 85 83

+46 70 885 83 62

BMC C1121b


Lund University Diabetes Centre, CRC, SUS Malmö, Entrance 72, House 91:12. SE-205 02 Malmö. Telephone: +46 40 39 10 00